Immune checkpoint inhibitor (keytruda, opdivo, yervoy, tecentriq, imfinzi, libtayo) denied as not FDA-approved for this use by UnitedHealthcare?

UnitedHealthcare covers immune checkpoint inhibitors (Keytruda/pembrolizumab, Opdivo/nivolumab, Yervoy/ipilimumab, Tecentriq/atezolizumab, Imfinzi/durvalumab, Libtayo/cemiplimab, and related agents) under the medical benefit when prescribed for cancer indications. This policy provides parameters for coverage of injectable oncology medications, including therapeutic radiopharmaceuticals, covered under the medical benefit based upon the National Comprehensive Cancer Network (NCCN) Drugs & Biologics Compendium, which lists appropriate drugs and biologics for specific cancers using US Food and Drug Administration (FDA)-approved disease indications and specific NCCN panel recommendations. UnitedHealthcare recognizes indications listed in the NCCN Drugs and Biologics Compendium with Categories of Evidence and Consensus of 1, 2A, and 2B as proven and medically necessary, and Category 3 as unproven and not medically necessary. Coverage is provided for the UnitedHealthcare preferred oncology product contingent on the diagnosis-specific criteria; coverage for any non-preferred product is contingent on both the Preferred Product Criteria and Diagnosis-Specific Criteria, and members new to therapy are required to use the preferred product unless they meet exception criteria. Preferred/non-preferred designations vary by indication—for example, in non-small cell lung cancer Keytruda Qlex is preferred; in head and neck cancers Keytruda Qlex is non-preferred; and in squamous cell skin cancer Libtayo is preferred while Keytruda, Keytruda Qlex, Opdivo, Opdivo Qvantig, and Unloxcyt are non-preferred. To qualify for a non-preferred product, the patient must have a history of intolerance or contraindication to a UnitedHealthcare preferred oncology product, and the physician must attest that the same intolerance, contraindication, or adverse event would not be expected with the non-preferred product. Keytruda is administered through the medical benefit but specialty pharmacy distribution is required: UnitedHealthcare classifies Keytruda as a specialty medication requiring prior authorization through OptumRx, typically placed on a high-cost specialty tier (Tier 5). Prior authorization is required, with reauthorization on a periodic basis, and specific PD-L1 expression thresholds (e.g., ≥50% for monotherapy first-line NSCLC) apply per the NCCN/FDA labels referenced in the policy.

- **Cite NCCN Category 1/2A recommendation for the exact indication**: UHC's own policy binds coverage to NCCN Compendium recommendations of Category 1, 2A, or 2B as proven and medically necessary . Quote the specific NCCN guideline page and category (e.g., NCCN NSCLC Guidelines list pembrolizumab + chemo as Category 1 for first-line metastatic non-squamous NSCLC; KEYNOTE-189 trial). - **Reference pivotal trial data supporting the FDA label**: For Keytruda in NSCLC cite KEYNOTE-024 (PD-L1 ≥50% monotherapy) and KEYNOTE-189/407 (combo with chemo); for Opdivo+Yervoy cite CheckMate-227/9LA; for Libtayo cite EMPOWER-Lung-1 and EMPOWER-CSCC-1; for Imfinzi cite PACIFIC (stage III NSCLC after chemoradiation); for Tecentriq cite IMpower150/133. - **Document preferred-product step therapy was met or is contraindicated**: Provide chart notes showing prior trial of the UHC preferred ICI with progression, intolerance, or a contraindication (e.g., active autoimmune disease, hypersensitivity), satisfying UHC's exception pathway as history of intolerance or contraindication to one of the UnitedHealthcare's preferred oncology products, and physician attests that the same intolerance, contraindication, or adverse event would not be expected to occur with the respective non-preferred product. - **Submit biomarker results**: Attach the PD-L1 IHC report (22C3/SP263), MSI/MMR or TMB testing report, and tumor histology confirming the FDA-labeled indication; for monotherapy NSCLC confirm PD-L1 expression positive ≥ 50% . - **Invoke ASCO and NCCN consensus**: ASCO Clinical Practice Guidelines (e.g., ASCO/ESMO guidelines for metastatic NSCLC, melanoma, RCC, HNSCC, urothelial carcinoma) concur with NCCN on ICI use; cite specific guideline year and recommendation grade. - **Cite UHC's medical-benefit step therapy carve-outs**: Continuation-of-therapy provisions apply when the member has been receiving the ICI; reference continuation of prior therapy within the past 365 days as grounds for approval without re-trying the preferred agent. - **Escalate to external/independent review with policy language**: Per practitioner experience, external reviews succeed when patients include a detailed timeline showing how UnitedHealthcare's denial contradicts their own published criteria, and independent medical reviewers appreciate clear, point-by-point rebuttals that reference the plan's policy language directly.

## UHC + Immune Checkpoint Inhibitors + "Not FDA-Approved" — Why This Denial Is Often Beatable

A UnitedHealthcare denial citing "not FDA-approved" for Keytruda, Opdivo, Yervoy, Tecentriq, Imfinzi, or Libtayo is almost always a compendium-recognition dispute, not a true off-label rejection. Under UHC's Oncology Medication Clinical Coverage Commercial Medical Benefit Drug Policy (eff. 04/01/2026), the operative coverage rule is not the FDA label alone — it is the NCCN Drugs & Biologics Compendium Category of Evidence and Consensus. UHC explicitly recognizes Category 1, 2A, and 2B indications as "proven and medically necessary," and only Category 3 as "unproven." That means an OptumRx reviewer who denies on "not FDA-approved" grounds without addressing the NCCN entry has misapplied the policy on its face.

### Reason-anchored mechanics

The correct appeal frame is compendium override, not experimental/investigational. Pull the most recent NCCN guideline page for the tumor type, screenshot the recommendation block showing the Category 1/2A/2B designation, and cite both the policy's own compendium clause and the Social Security Act §1861(t)(2) framework that established compendium-based coverage as the federal standard for oncology (mirrored in most commercial medical policies, including UHC's). If the indication is genuinely off-compendium, pivot to the Pinto v. Aetna, 762 F.3d 1115 (10th Cir. 2014) ERISA burden-of-proof argument: the plan, not the patient, bears the burden of producing record evidence that a treatment is experimental. A generic "not FDA-approved" letter does not satisfy that burden.

### Insurer-specific procedural levers

• Channel routing: Keytruda and the rest of the class are medical-benefit J-code drugs (J9271, J9299, J9023, J9022, J9173, J9119) administered buy-and-bill but routed through OptumRx specialty PA. Filing through the pharmacy-benefit portal will get auto-denied — use the UHC Provider Portal → Prior Authorization and Notification (PAAN) → Oncology path, which routes to the OptumRx oncology clinical team operating under UHC's medical policy.
• Peer-to-peer: Request a P2P with an oncologist reviewer, not a generalist. UHC contracts with OptumRx Specialty Clinical for hematology/oncology P2Ps; insist on a board-certified onc per UHC's own Medical Necessity Determination protocol.
• External review: ERISA plans get IRO review under 29 CFR §2590.715-2719; fully insured plans go to the state DOI (CA DMHC IMR has a >70% overturn rate on oncology compendium disputes).
• MA members: Use the 42 CFR §422.566 reconsideration pathway and cite NCD 110.21 (off-label anticancer drug coverage via compendia) — UHC MA plans cannot apply criteria stricter than NCD 110.21.

### Tactical tip

In the appeal letter's first paragraph, quote UHC's policy verbatim — "Categories of Evidence and Consensus of 1, 2A, and 2B as proven and medically necessary" — and attach the NCCN recommendation page. This converts the appeal from a clinical debate into a policy-compliance argument the reviewer cannot refuse without writing a contradictory rationale, which itself becomes appealable under 29 CFR §2560.503-1(g)'s specific-reason disclosure rule.